Opinions
The Panic-Proof Portfolio (Stockchase Research)
Entrada Therapeutics, Inc.
TRDA-Q
PAST TOP PICK
Dec 10, 2024
$20.975
Stock price when the opinion was issued
Pharma & Healthcare
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
You might be interested:
TOP PICK
Stockchase Research Editor: Michael O'Reilly
This pharma company produces clinical stage drugs that aid the delivery of other therapeutics and they have been advancing a portfolio of RNA based programs. It trades at 6x trailing earnings, under 1.5x book and supports a 32% ROE and has growing cash reserves. We recommend setting a stop-loss at $13, looking to achieve $21 -- upside potential of 27%. Yield 0%
(Analysts’ price target is $21.50)
Pharma & Healthcare
PAST TOP PICK
(A Top Pick Oct 08/24, Down 2.3%)Stockchase Research Editor: Michael O'Reilly
Our PAST TOP PICK with TRDA has triggered its stop at $16. To remain disciplined, we recommend covering the position at this time. This will result in a net investment gain of 12%, when combined with our previous guidance.
Pharma & Healthcare
Our PAST TOP PICK with TRDA has achieved its target at $21. To remain disciplined, we recommend covering half the position at this time and trailing up the stop (from $13) to $16.